Robin Turinetti
Family · Melbourne, FLNPI 1285973453
Payments from drug & device makers
Across 223 payments — averaging $77.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Grifols USA, LLC$10K
- AstraZeneca$3K
- GSK$2K
- Grifols Shared Services North America, Inc.$480
- Boehringer Ingelheim$337
- Jazz Pharmaceuticals Inc.$259
- plus $1K from 18 others
What the payments were for
- Consulting fees$7204%
- Speaking & faculty fees$6,40037%
- Travel & lodging$2,48714%
- Food & beverage$7,60944%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Grifols USA, LLC | 52 | $10,486 |
| AstraZeneca | 50 | $2,776 |
| GSK | 59 | $1,557 |
| Grifols Shared Services North America, Inc. | 1 | $480 |
| Boehringer Ingelheim | 16 | $337 |
| Jazz Pharmaceuticals Inc. | 7 | $259 |
| Axsome Therapeutics, Inc. | 5 | $199 |
| Harmony Biosciences LLC | 3 | $184 |
| Philips North America LLC | 6 | $168 |
| Novo Nordisk | 2 | $147 |
| United Therapeutics Corporation | 2 | $134 |
| Amgen | 1 | $122 |
| Insmed, Inc. | 4 | $85 |
| Verona Pharma, Inc. | 3 | $77 |
| Azurity Pharmaceuticals, Inc. | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Mylan Specialty L.p. | 1 | $28 |
| Electromed, Inc. | 2 | $24 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $24 |
| Lilly USA, LLC | 1 | $22 |
| Sanofi | 1 | $17 |
| Inogen, Inc. | 1 | $16 |
| Baxter Healthcare | 1 | $13 |
| Advanced Respiratory, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,233 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 67 | $63,420 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 46 | $45,134 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $13,758 |
| Spiriva RespimatTiotropium Bromide | 12 | $7,649 |
| Arnuity ElliptaFluticasone Furoate | 18 | $4,615 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,813 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 32 | $1,463 |
| Ventolin HfaAlbuterol Sulfate | 15 | $1,426 |
| Ipratropium Bromide | 11 | $740 |
| Montelukast Sodium | 42 | $481 |
| Azelastine Hcl | 11 | $304 |
| Famotidine | 14 | $265 |
| Fluticasone Propionate | 19 | $239 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,557 | $81,792116 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,776 | $47,94757 claims |
| Boehringer IngelheimSpiriva Respimat | $337 | $7,64912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.
Other family in Melbourne
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.